Product Information
AMITIZA 24 MCG CAPSULE is a brand product labeled by SpecGx LLC, priced at $6.4489 per EA under NDC 23635052460. Its NADAC has been published 111 times since Aug 21, 2024.
FDA first approved this application on Jan 31, 2006. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
The High Outlier badge above means this manufacturer's average price in the lubiprostone market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
24 ug/1
Manufacturer
SpecGx LLCNDC
23635052460
Classification
Brand
Dosage Form
CAPSULE, GELATIN COATED
Route
ORAL
Effective Date
4/22/2026
Active Ingredients
LUBIPROSTONEApproval Type
New Drug (NDA)
FDA Application
NDA021908FDA Approved
1/31/2006
TE Code
AB
On Market Since
4/1/2024
Pharmacological Classes
Price Statistics
The NADAC for AMITIZA 24 MCG CAPSULE has been published 111 times since Aug 21, 2024, and over the history we have for it it has held within roughly two percent of its current level. The table below summarizes its recorded NADAC range and movement.
| Current price | $6.4489 per EA |
|---|---|
| All-time high | $6.4523 (Nov 12, 2025) |
| All-time low | $6.4337 (Oct 23, 2024) |
| 52-week high | $6.4523 |
| 52-week low | $6.4461 |
| Median price | $6.4463 |
| Average price | $6.4454 |
| Largest weekly change | -0.2% (Sep 18, 2024) |
| Weeks tracked | 111 |
| Tracking since | Aug 21, 2024 |
Generic Alternatives
The matcher finds 2 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 90% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
SpecGx LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
lubiprostone market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Chloride Channel Activator class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of AMITIZA 24 MCG CAPSULE?
The current National Average Drug Acquisition Cost (NADAC) for AMITIZA 24 MCG CAPSULE, manufactured by SpecGx LLC, is $6.4489 per EA (NDC 23635052460), effective Sep 30, 2026.
How has the price of AMITIZA 24 MCG CAPSULE changed over time?
Over the history we have for it, the NADAC for AMITIZA 24 MCG CAPSULE has held within roughly two percent of its current level. It has been tracked across 111 weekly CMS publications since Aug 21, 2024.
What are the highest and lowest recorded NADAC prices for AMITIZA 24 MCG CAPSULE?
Since Aug 21, 2024, the NADAC for AMITIZA 24 MCG CAPSULE has ranged from a low of $6.4337 (Oct 23, 2024) to a high of $6.4523 (Nov 12, 2025), with a median of $6.4463 per EA.
Are there cheaper alternatives to AMITIZA 24 MCG CAPSULE?
Yes. 2 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, LUBIPROSTONE 24 MCG CAPSULE, is $0.6507 per EA — about 90% below AMITIZA 24 MCG CAPSULE.
Who manufactures AMITIZA 24 MCG CAPSULE?
AMITIZA 24 MCG CAPSULE (NDC 23635052460) is labeled by SpecGx LLC, and CMS classifies it as a brand product.